CANADA LIFE ASSURANCE Co Trims Holdings in iShares Biotechnology ETF (NASDAQ:IBB)

CANADA LIFE ASSURANCE Co lowered its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 1.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 108,093 shares of the financial services provider’s stock after selling 1,175 shares during the quarter. CANADA LIFE ASSURANCE Co owned approximately 0.23% of iShares Biotechnology ETF worth $14,280,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Raymond James Financial Inc. acquired a new position in iShares Biotechnology ETF in the fourth quarter valued at approximately $55,010,000. Gray Foundation grew its stake in iShares Biotechnology ETF by 25.2% during the 4th quarter. Gray Foundation now owns 164,872 shares of the financial services provider’s stock worth $21,798,000 after buying an additional 33,179 shares during the last quarter. Aprio Wealth Management LLC acquired a new stake in iShares Biotechnology ETF in the fourth quarter worth $18,476,000. Avalon Trust Co lifted its stake in iShares Biotechnology ETF by 0.7% in the fourth quarter. Avalon Trust Co now owns 127,893 shares of the financial services provider’s stock valued at $16,909,000 after buying an additional 935 shares during the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. acquired a new position in shares of iShares Biotechnology ETF during the fourth quarter valued at $11,370,000. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Up 0.4 %

IBB stock opened at $118.29 on Monday. The stock has a market cap of $5.29 billion, a PE ratio of 24.21 and a beta of 0.84. The firm’s 50-day simple moving average is $129.81 and its 200 day simple moving average is $135.71. iShares Biotechnology ETF has a fifty-two week low of $107.43 and a fifty-two week high of $150.57.

iShares Biotechnology ETF Increases Dividend

The business also recently announced a dividend, which was paid on Friday, March 21st. Investors of record on Tuesday, March 18th were given a $0.1212 dividend. The ex-dividend date of this dividend was Tuesday, March 18th. This is a positive change from iShares Biotechnology ETF’s previous dividend of $0.06.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.